about
Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia.[Results of treatment with 2-chlorodeoxyadenosine in refractory or relapsed Langerhans cell histiocytosis. Study of 9 patients]Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score.Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group.Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trialVariant three-way translocation of inversion 16 in AML-M4Eo confirmed by fluorescence in situ hybridization analysis.Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.Cytogenetic risk stratification in chronic myelomonocytic leukemia.The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis.Myelodysplastic syndromes: an update on molecular pathology.Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin.Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes.Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes.Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis.Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group.Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.Excess mortality in the myelodysplastic syndromes.Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.Apoptotic induction in transformed follicular lymphoma cells by Bcl-2 downregulation.Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab).Uncertain role of increased intensity chemotherapy with high-dose cytarabine in acute promyelocytic leukemia.MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia.Images in clinical medicine. Myeloid sarcoma.Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study).Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease.Application of FISH 7q in MDS patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics: does -7/7q- detection by FISH have prognostic value?CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy.Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors.Sustained complete molecular remission after imatinib discontinuation due to severe aplastic anemia.Oxidative imbalance in low/intermediate-1-risk myelodysplastic syndrome patients: The influence of iron overload.Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML.Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.Guillain-Barré syndrome associated with cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.Bcl-6 mutation status provides clinically valuable information in early-stage B-cell chronic lymphocytic leukemia.Immunophenotype of acute myeloid leukemia with NPM mutations: prognostic impact of the leukemic compartment size.Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real-world comparison.
P50
Q33235067-9100ADFF-40D2-4508-A572-048D3B48FA95Q33337173-A98330CD-F130-4BD2-81A5-FD9FFB40E3DEQ33419220-840167F0-72D3-4A6E-89DB-F90508B1E1E3Q33428556-62CBBEDD-C40D-4CD9-B2EF-5F1179992A4AQ33587563-CB8F31A2-6778-48C5-AF2A-022982D7B7A0Q33600680-44DB0619-B629-4824-BB87-1E737A617BC4Q33707423-534687D1-B1B5-429C-8055-B9C62D94DA73Q34522736-C8EA7A3A-DC7B-44D3-AA2F-26C25DF81212Q34612592-A53B26D0-1F04-4F5E-AD31-78F070FFFA47Q36254225-7AF52C78-ECB3-4636-A599-CC83C0F25568Q36544646-CD4EF24A-259D-4C4D-AC41-E0136D1B6822Q37334952-A8414118-523D-4840-9A66-29F2907C3D08Q37800283-840BC50F-6BD7-4230-AA9F-A83294474A2BQ38815519-1C1CBAC0-C94A-42CB-A8EF-E16A1FAE7F78Q38827726-DC4BDFFF-35CE-4601-8D14-AB85AF1D389CQ38844894-C7C73E2B-B471-48D7-8B9B-69EBD3497DE2Q38859549-439C99F2-EBA1-4491-9E44-CD4F910B6B39Q39811365-44759591-836C-439B-9D3A-9C083D63C5E7Q40160900-7A548BF5-60F3-4A8C-AAE1-59470DF46E7CQ40429557-5065D939-E348-4C62-94F3-9A0939D52678Q40470007-19248D78-2A89-4087-A15C-B1130C29F77CQ40974681-34D304DB-5E8F-42F9-B255-D3D547363FD7Q41014540-FA748F2F-116B-4A34-B426-3A6F0778C8B7Q42277126-1829FB38-683B-4F8A-9400-E267A1FA4655Q43830966-72350E2C-DB5D-411D-B62B-CFE92AD7DA66Q43850689-5AD65B51-FE3F-473A-8F71-7BD892FD45E6Q44031102-C4E6B012-47F2-41A9-8C95-502EC8C1408DQ44304097-0EA74444-2462-4D72-8479-F0826926DDC7Q45800079-3A2EEF94-D379-4F35-A10D-4C950A197A31Q45904545-8736EE12-C4B9-4DB3-A0F6-BB03A137B6A3Q46192339-04CADDE1-F9A2-4EDE-BB2F-66B207B8FA63Q46301898-02C3BF4F-65D0-41F9-8EF7-8CDD571BCDCCQ46346398-69CA7057-E508-4A39-ABEA-C0DBFCA8C75FQ46357663-B0FCB1D8-02DD-467E-82CA-3BCE0674CCCFQ46571589-79EB22DB-8AAC-4BD0-99AF-5989E1B02FACQ46656690-75079DCD-C6E5-4F8F-8251-272F440590E0Q46692842-FE64F255-A556-4C47-B545-71E1758375EFQ47207480-D74735F2-0781-4EF7-AF86-6DCEBBF523D4Q47428574-1FF856E1-8820-4AD2-AB44-C34FFA106ADEQ47618244-B0B6DCD0-2CD7-41FA-BB0E-F7359006B54E
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mar Tormo
@ast
Mar Tormo
@en
Mar Tormo
@es
Mar Tormo
@nl
Mar Tormo
@sl
type
label
Mar Tormo
@ast
Mar Tormo
@en
Mar Tormo
@es
Mar Tormo
@nl
Mar Tormo
@sl
prefLabel
Mar Tormo
@ast
Mar Tormo
@en
Mar Tormo
@es
Mar Tormo
@nl
Mar Tormo
@sl
P106
P31
P496
0000-0001-9622-1649